Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxytetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.70 |
| ▸ | MEN1 | O00255 | 9/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.70 |
| ▸ | USP2 | O75604 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | RECQL | P46063 | 5/20 | 0.70 |
| ▸ | THRB | P10828 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxytetracycline SCHEMBL2899 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782519 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782617 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL18048891 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL2614977 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782467 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL5507247 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133474 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL21133472 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 | |
| Oxytetracycline SCHEMBL13782478 | 1.00 | TDP1 (0.70) | TDP1MEN1KMT2AKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150056160-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | claimed |
| US-20130252334-A1 | METHOD OF USING TET-INDUCIBLE TRANSGENES | UNIVERSITY OF ROCHESTER (US) | 2013-09-26 | — | — | US | claimed |
| WO-2012048318-A2 | METHOD OF USING TET-INDUCIBLE TRANSGENES | UNIVERSITY OF ROCHESTER (US) | 2012-04-12 | — | — | WO | claimed |
| US-5604208-A | CONTAINING GENTAMICIN | QUIMICA AGRONOMICA DE MEXICA, S.DE.R.L.MI. (MX) | 1997-02-18 | — | — | US | claimed |
| EP-3262183-B1 | BACTERIA IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST | MASTAPLEX LTD (NZ) | 2023-06-07 | — | — | EP | disclosed |
| US-20220079899-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | UNITED STATES GOVERNMENT | 2022-03-17 | — | — | US | disclosed |
| US-20210172001-A1 | BACTERIA IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST | MASTAPLEX LTD (NZ) | 2021-06-10 | — | — | US | disclosed |
| US-10829796-B2 | Bacteria identification and antimicrobial susceptibility test | MASTAPLEX LIMITED (NZ) | 2020-11-10 | — | — | US | disclosed |
| US-20180245124-A1 | BACTERIA IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST | MASTAPLEX LIMITED (NZ) | 2018-08-30 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| EP-3262183-A1 | BACTERIA IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST | Mastaplex Limited (NZ) | 2018-01-03 | — | — | EP | disclosed |
| WO-2017100825-A1 | A PHARMACEUTICAL COMPOSITION AND USES THEREFOR | GILLIGAN ROBERT (AU) | 2017-06-22 | — | — | WO | disclosed |
| EP-1354581-A1 | POROUS SUBSTANCE AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-0533690-B1 | PHOSPHOLIPID-COATED MICROCRYSTALS: INJECTABLE FORMULATIONS OF WATER-INSOLUBLE DRUGS | PHARMA LOGIC INC (US) | 1999-06-16 | — | — | EP | disclosed |
| US-5739283-A | Prevention of invasive pulmonary aspergillosis with serine proteinase inhibitors | THE OHIO STATE RESEARCH FOUNDATION (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0566291-A1 | Antibiotic preparation and use of the same in plants | QUIMICA AGRONOMICA DE MEXICO, S. DE R.L. MI. (MX) | 1993-10-20 | — | — | EP | disclosed |
| EP-0533690-A4 | PHOSPHOLIPID-COATED MICROCRYSTALS: INJECTABLE FORMULATIONS OF WATER-INSOLUBLE DRUGS | — | 1993-04-14 | — | — | EP | disclosed |
| EP-0533690-A1 | PHOSPHOLIPID-COATED MICROCRYSTALS: INJECTABLE FORMULATIONS OF WATER-INSOLUBLE DRUGS | PHARMA-LOGIC, INC. (US) | 1993-03-31 | — | — | EP | disclosed |
| US-5091187-A | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs | SKYEPHARMA AG (CH) | 1992-02-25 | — | — | US | disclosed |
| WO-1991016068-A1 | PHOSPHOLIPID-COATED MICROCRYSTALS: INJECTABLE FORMULATIONS OF WATER-INSOLUBLE DRUGS | HAYNES DUNCAN H (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079899-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | ENPP1, ENPP3, ENPP2 | TDP1 241/4885MEN1 2270/4885KMT2A 4491/4885 |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | TDP1 1003/4885MEN1 3697/4885KMT2A 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.